Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06923527 · ClinicalTrials.gov registry record · Phase 2
Circulating Tumor DNA
A Phase 2 study of ER+ Breast Cancer, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT06923527: Recruiting Phase 2 study of ER+ Breast Cancer, sponsored by Yale University.
NCT06923527 is a Phase 2 study of ER+ Breast Cancer that is actively recruiting participants, run by Yale University. The registered enrollment target is 50 participants, below the 83-participant average among 8 other ER+ Breast Cancer trials with a reported enrollment target (40% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06923527, a Phase 2 study of ER+ Breast Cancer, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.
Primary Outcome
This study evaluates whether treatment with elacestrant improves the clearance of circulating tumor DNA (ctDNA) in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Patients included in the study have detectable ctDNA in their plasma but show no evidence of metastatic disease on imaging, and the results will be compared against historical control data.
Conditions Studied
Interventions
- DRUG Elacestrant
Study Locations (7)
Connecticut
- Yale University - New Haven
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
Maryland
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Montefiore Einstein Comprehensive Cancer Center - The Bronx
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06923527 shows while recruiting
NCT06923527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 83-participant average among 8 other ER+ Breast Cancer trials with a reported enrollment target (40% lower).
The record links to 1 condition, with ER+ Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Elacestrant is the first listed.
NCT06923527 lists 7 locations in 7 states (Connecticut, District of Columbia, Maryland).
Frequently Asked Questions
What is clinical trial NCT06923527 about?
NCT06923527 is a clinical study titled "Circulating Tumor DNA". This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.
What is the current status of trial NCT06923527?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-09-30. Estimated completion is 2027-09.
What conditions does trial NCT06923527 study?
This clinical trial studies the following conditions: ER+ Breast Cancer.
What interventions are being tested in trial NCT06923527?
The interventions under investigation include: Elacestrant (DRUG).
Who is sponsoring clinical trial NCT06923527?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06923527 being conducted?
This trial has 7 study locations across Connecticut, District of Columbia, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ER+ Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06923527's enrollment target sits among peer trials
50 6th of 8 higher than 3 of 8 other ER+ Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ER+ Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
RECRUITING · Phase 2
-
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
RECRUITING · Phase 2
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Breast Re-irradiation After Second Ipsilateral Lumpectomy
RECRUITING · NA
-
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI